Table 2.
Historical Control Characteristics
| Bevacizumab | LITT | |
|---|---|---|
| n | 50 | 28 |
| Age at treatment (mean) | 61.4 | 61.3 |
| Gender | ||
| Male (n,%) | 33 (66%) | 17 (61%) |
| Female (n, %) | 17 (34%) | 11 (39%) |
| Race | ||
| Caucasian (white, non-Hispanic) | Not reported | 22 (79%) |
| median KPS score | 80 | 90 |
| Steroids pre-intervention | ||
| on Dexamethasone (n,%) | 34 (68%) | 10 (36%) |
| Tumor | ||
| WHO grade IV (n,%) | 50 (100%) | 28 (100%) |
| Frontline/initial surgery | ||
| Gross total (n,%) | 19 (38%) | 18 (64%) |
| Subtotal (n,%) | 15 (30%) | 5 (18%) |
| Biopsy or unclear (n,%) | 16 (32%) | 5 (18%) |
| MGMTp status | ||
| Unmethylated | Not reported | 13 (46%) |
| Methylated | Not reported | 12 (43%) |
| Indeterminate | Not reported | 3 (11%) |
| IDH1 status | ||
| Wildtype | Not reported | 24 (86%) |
| Mutated | Not reported | 0 (0%) |
| Unknown | Not reported | 3 (14%) |
Demographic and tumor characteristics of the two control groups. Bevacizumab controls reflected historical controls available in the literature (31). The LITT control group were historical controls with recurrent GBM who lacked an IDH1 mutation. Additional details available in Supplementary Table 2.